Compare FSSL & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSSL | FTH |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 885.2M | 860.0M |
| IPO Year | N/A | 2021 |
| Metric | FSSL | FTH |
|---|---|---|
| Price | $11.31 | $27.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 375.1K | 264.5K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 15.05% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $203,111,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.60 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $10.75 | $17.50 |
| 52 Week High | $14.49 | $37.90 |
| Indicator | FSSL | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 48.87 |
| Support Level | $11.16 | $22.47 |
| Resistance Level | $11.36 | $31.61 |
| Average True Range (ATR) | 0.20 | 3.25 |
| MACD | 0.04 | -0.40 |
| Stochastic Oscillator | 98.08 | 28.14 |
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing primarily in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest primarily in a portfolio of secured and unsecured floating and fixed rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.